| Assessment Status | Rapid Review Complete |
| HTA ID | 23047 |
| Drug | Dupilumab |
| Brand | Dupixent® |
| Indication | Dupilumab (Dupixent®) is indicated for the treatment of adults and adolescents 12 years and older, weighing at least 40 kg, with eosinophilic oesophagitis (EoE) who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy. |
| Assessment Process | |
| Rapid review commissioned | 26/07/2023 |
| Rapid review completed | 07/09/2023 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of dupilumab for this indication compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
